Table 1.
L-caldesmon expression in colorectal cancer cases and its relationship to clinical and pathological characteristics.
| Total (n = 262) * |
l-CaD Positive n = 187 (71.4%) |
l-CaD Negative n = 75 (28.6%) |
p Value | ||
|---|---|---|---|---|---|
| Sex | Male | 128 (48.9%) | 93 | 35 | N.S. |
| Female | 133 (50.8%) | 93 | 40 | ||
| Age (cut-off 80 y) | Old ≥ 79 | 133 (50.8%) | 96 | 37 | N.S. |
| Young < 79 | 129 (49.2%) | 91 | 38 | ||
| Age (cut-off 50 y) | Old ≥ 50 | 255 (79.3%) | 182 | 73 | N.S. |
| Young < 50 | 7 (2.7%) | 5 | 2 | ||
| Histological Type | Adenocarcinoma | 230 (87.8%) | 165 | 65 | N.S. |
| Mucinous adenocarcinoma | 22 (8.4%) | 15 | 7 | ||
| Others # | 6 (2.2%) | 5 | 1 | ||
| UICC | 0, I, II, IIA, IIC | 76 (29.0%) | 57 | 19 | N.S. |
| III, IIIA, IIIB, IIIC, IV, IVA, IVB, IVC | 154 (58.8%) | 108 | 46 | ||
| T-stage | T1, T2, T3 | 182 (69.7%) | 130 | 52 | N.S. |
| T4, T4a, T4b | 79 (30.2%) | 56 | 23 | ||
| N-stage | N0, N1, N1a, N1b, N1c | 178 (67.9%) | 125 | 53 | N.S. |
| N2, N2a, N2b, X | 81 (30.9%) | 60 | 21 | ||
| M-stage | M0, M1a | 218 (83.5%) | 155 | 63 | N.S. |
| M1b, M1c | 43 (16.4%) | 31 | 12 | ||
| Stage Grouping | Lymph node stage I, lymph node stage II | 110 (41.9%) | 70 | 40 | 0.02 |
| Primary stage I, Primary stage II, Primary stage III |
152 (58.0%) | 117 | 35 |
Table Footnote. * Differences in the total number were due to missing data. # Other histological types were signet ring cell carcinoma, serrated adenocarcinoma, mixed adeno-neuroendocrine carcinoma, mucinous carcinoma, combined/mixed carcinoid and adenocarcinoma, and in situ adenocarcinoma. Tumor stages at the time of tumor diagnosis were re-assessed according to the 8th edition TNM classification for tumor staging. Abbreviations: l-CaD, low molecular weight caldesmon, N.S., non-significant (>0.05); TNM, T: tumor, N: lymph node; M: metastasis; UICC, Union for International Cancer Control. A detailed explanation of the TNM stages can be found in the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual [27].